The Burke Neurological Institute (BNI) in White Plains is testing a completely different approach to stopping Alzheimer’s disease. BNI, a BCW member and an affiliation of Weill Cornell Medicine, in partnership with the Alzheimer’s Disease Cooperative Study (ADCS) at University of California San Diego and Columbia University Irving Medical Center, have launched a national clinical trial to investigate the therapeutic potential of a form of benfotiamine, a synthetic version of vitamin B1 (thiamine), as a treatment for mild cognitive impairment (MCI) and early Alzheimer’s disease (AD). “The approach of using benfotiamine in patients with mild Alzheimer’s is very promising,” said […]